PharmaEssentia is committed to advancing the treatment of Essential Thrombocythemia (ET) through rigorous clinical research. The company is currently enrolling participants for two significant trials:
-
A Phase 3 Trial: This open-label, multicenter, randomized, active-controlled trial evaluates the efficacy, safety, tolerability, and pharmacokinetics of ropeginterferon alfa-2b-njft after 12 months of treatment compared with anagrelide (ANA) as second-line therapy for adult patients with ET who have shown resistance or intolerance to hydroxyurea (HU). The trial is registered under ClinicalTrials.gov: NCT04285086.
-
A Phase 2b Trial: This single-arm, multicenter trial assesses the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adult patients with ET in the US and Canada. The trial is registered under ClinicalTrials.gov: NCT05482971.
For more information about these trials, interested parties can contact the study information center at 1-800-999-2449 or email the PharmaEssentia Medical Information team at medinfo@pharmaessentia-us.com.
